CROI 2017 Program and Information

Program and Agenda

Poster P-I2 MAINTENANCE: SECOND- AND THIRD-LINE THERAPY Poster Hall - 4 EF2:30 PM - 4:00 PM 457 QUALITY OF LIFE IMPROVEMENT DURING SECOND-LINE THERAPY IN RESOURCE-LIMITED SETTINGS Thiago S. Torres 1 , Linda J. Harrison 1 , Alberto M. La Rosa 2 , Lu Zheng 1 , Sandra W. Cardoso 3 , Selvamuthu Poongulali 4 , McNeil Ngongondo 5 , Ann Collier 6 , Michael D. Hughes 1 , for the AIDS Clinical Trials Group (ACTG) A5273 Study Group 1 Harvard Univ, Boston, MA, USA, 2 Asociación Civil Impacta Salud y Educación, Lima, Peru, 3 Inst Nacional de Infectologia (INI/Fiocruz), Rio de Janeiro, Brazil, 4 YRGCARE Med Cntre, Chennai, India, 5 UNC-Proj Malawi, Lilongwe, Malawi, 6 Univ of Washington, Seattle, WA, USA 458 PROMISING RESULTS OF DOLUTEGRAVIR+LAMIVUDINE MAINTENANCE IN ANRS 167 LAMIDOL TRIAL Veronique Joly 1 , Charles Burdet 2 , Roland Landman 3 , François Raffi 4 , Christine Katlama 5 , André Cabié 6 , Aida Benalycherif 3 , Gilles Peytavin 1 , Diane Descamps 1 , Yazdan Yazdanpanah 2 1 Hôpital Bichat, Paris, France, 2 INSERM, Paris, France, 3 IMEA, Paris, France, 4 CHU Hotel-Dieu Nantes, Nantes, France, 5 Pierre and Marie Curie Univ, Paris, France, 6 CHU Fort de France, Fort de France, Martinique, France 459 ADVERSE DRUG REACTIONS AMONG PATIENTS RECEIVING SECOND-LINE ART IN SOUTH AFRICA Dorina Onoya 1 , Kamban Hirasen 1 , Lawrence Long 1 , Matthew Fox 2 1 Univ of the Witwatersrand, Johannesburg, South Africa, 2 Boston Univ, Boston, MA, USA 460 LONG-TERMEFFICACY OF DOLUTEGRAVIR 50MG BID IN INI- RESISTANT FAILING HIV-1 SUBJECTS Antonella Castagna 1 , Micol Ferrara 2 , Laura Galli 3 , Laura Comi 4 , Gaetana Sterrantino 5 , Giovanni Cenderello 6 , Mauro Zaccarelli 7 , Emanuele Focà 8 , Andrea Roncadori 9 , Adriano Lazzarin 10 1 Univ Vita-Salute San Raffaele, Milan, Italy, 2 Univ di Torino, Torino, Italy, 3 Ospedale San Raffaele, Milano, Italy, 4 Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy, 5 Azienda Ospedaliero Univ Careggi, Firenze, Italy, 6 Galliera Hosp, Genoa, Italy, 7 Natl Inst for Infectious Diseases, Rome, Italy, 8 ASST Spedali Civili di Brescia, Brescia, Italy, 9 CINECA, Casalecchio di Reno, Italy, 10 San Raffaele Vita-Salute Univ, Milan, Italy Poster P-J3 INTEGRASE STRAND TRANSFER INHIBITOR RESISTANCE Poster Hall - 4 EF 2:30 PM - 4:00 PM 495 EVOLUTION OF ARCHIVED HIV-1 QUASISPECIES IN INDIVIDUALS TREATEDWITH DOLUTEGRAVIR Pierre Gantner 1 , Guinevere Q. Lee 2 , David Rey 1 , Thibault Mesplede 3 , Marialuisa Partisani 1 , Geneviève Beck-Wirth 4 , Jean-Pierre Faller 5 , Martin Martinot 6 , Mark Wainberg 3 , Samira Fafi-Kremer 1 1 Hôpitaux Univ de Strasbourg, Strasbourg, France, 2 BC Cntr for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada, 3 McGill Univ, Montreal, Quebec, Canada, 4 Groupe Hosp Regional–Mulhouse Sud Alsace, Mulhouse, France, 5 Hôpital Nord Franche Comté, Belfort, France, 6 Hôpital Civil de Colmar, Colmar, France

Poster Sessions • Tuesday

CROI 2017 89